Literature DB >> 19521405

Complexity of the association between psoriasis and comorbidities.

Tamar Nijsten1, Marlies Wakkee.   

Abstract

Multiple observational studies have recently demonstrated associations between psoriasis and several comorbidities--especially metabolic syndrome and cardiovascular disease, and now osteoporosis. It has been hypothesized that elevated levels of tumor necrosis factor-alpha are a biological explanation for the observed associations. In this commentary, we discuss the complexity of associations between psoriasis and comorbidities, possible residual confounding, the limitations of observational studies in proving causality, absolute versus relative risk differences, and the clinical relevance and possible clinical impact of "upgrading" psoriasis to a systemic disease.

Entities:  

Mesh:

Year:  2009        PMID: 19521405     DOI: 10.1038/jid.2009.55

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  26 in total

1.  Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.

Authors:  Tej Pratap Singh; Barbara Huettner; Harald Koefeler; Gerlinde Mayer; Isabella Bambach; Katrin Wallbrecht; Michael P Schön; Peter Wolf
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Alternative models of comorbidity: a framework for the interpretation of epidemiological association studies.

Authors:  Jochen Schmitt; Stephan Weidinger
Journal:  J Invest Dermatol       Date:  2014-02       Impact factor: 8.551

3.  Which Psoriasis Patients Develop Psoriatic Arthritis?

Authors:  Kristine Busse; Wilson Liao
Journal:  Psoriasis Forum       Date:  2010

4.  [Genome-associated studies in chronic inflammatory dermatoses].

Authors:  E Rodríguez; S Weidinger
Journal:  Internist (Berl)       Date:  2014-02       Impact factor: 0.743

5.  Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy.

Authors:  Linda A Feagins; Avegail Flores; Cristina Arriens; Christina Park; Terri Crook; Andreas Reimold; Geri Brown
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-10       Impact factor: 2.566

6.  Risk and predictors of cardiovascular disease in psoriasis: a population-based study.

Authors:  Hilal Maradit-Kremers; Ross A Dierkhising; Cynthia S Crowson; Murat Icen; Floranne C Ernste; Marian T McEvoy
Journal:  Int J Dermatol       Date:  2013-01       Impact factor: 2.736

Review 7.  The burden of moderate to severe psoriasis: an overview.

Authors:  Giovanna Raho; Daniela Mihajlova Koleva; Livio Garattini; Luigi Naldi
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

Review 8.  Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

9.  Potential role of ustekinumab in the treatment of chronic plaque psoriasis.

Authors:  Santo Raffaele Mercuri; Luigi Naldi
Journal:  Biologics       Date:  2010-05-25

Review 10.  Lipid disturbances in psoriasis: an update.

Authors:  Aldona Pietrzak; Anna Michalak-Stoma; Grazyna Chodorowska; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2010-07-20       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.